vTv Therapeutics Starts Phase 2a Diabetes Study
The company has randomized the first participant in a pilot trial testing cadisegliatin in Type 1 diabetes patients.
Updated on Oct. 27, 2026 in Diabetes
Live Poll
Is now a good time to participate in experimental clinical trials for chronic condition treatments?
vTv Therapeutics has begun a Phase 2a pilot study to evaluate the efficacy of cadisegliatin in adults with Type 1 diabetes. The trial assesses how this liver-selective glucokinase activator performs alongside existing hybrid closed-loop insulin delivery systems.
Why it matters
The study aims to determine if cadisegliatin can improve glycemic control and lower hypoglycemia risks for patients who already utilize automated insulin technology. Results from this trial will provide complementary data to the company's recent Phase 3 efforts.
The study involves 40 adults with Type 1 diabetes who have used hybrid closed-loop systems for at least three months, with treatment lasting six weeks. The trial measures postprandial glucose levels during standardized mixed-meal tolerance tests.
The players
vTv Therapeutics
This is a clinical-stage pharmaceutical company based in High Point, North Carolina, that focuses on the development of oral, small molecule drug candidates.
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
The details
The double-blind, placebo-controlled crossover study evaluates cadisegliatin, which has received Breakthrough Therapy designation from the FDA. Researchers are specifically monitoring participants using continuous glucose monitoring to compare outcomes against insulin-only therapy.
Timeline
October 27, 2026: The first participant was randomized in the Phase 2a study.
October 2026: vTv Therapeutics completed enrollment for its Phase 3 CATT1 study.
Health Landscape
This study follows the development pathway established by the FDA Breakthrough Therapy designation for cadisegliatin. It reflects a shift toward refining existing insulin delivery systems with specialized small molecule activators to achieve better glycemic targets.
This trial targets improvements for the 2.1 million Americans with Type 1 diabetes who currently manage their condition with insulin. If successful, the treatment could offer a new tool for those already using automated systems to reach target A1C levels more consistently.
The takeaway
This trial investigates whether combining novel oral medications with modern insulin delivery can optimize blood sugar management. Patients interested in future treatment options should monitor clinical registry updates for progress regarding trial outcomes.
Further reading
For more information on current clinical research, visit the Diabetes section.
More information
View the Phase 2a clinical trial details on the official government registry.
Source note: This article includes information reported by The Manila times.
Live Poll
Is now a good time to participate in experimental clinical trials for chronic condition treatments?
